Biocon Ltd. It was founded in 1978 by Kiran Mazumdar-Shaw, a pioneer in the Indian biotechnology industry. Initially, Biocon focused on the production of industrial enzymes but later expanded its portfolio to include a wide range of biopharmaceuticals.

The company's headquarters is situated in the Biocon Park, Bengaluru, which is a state-of-the-art facility spread across 108 acres. It houses research and development laboratories, manufacturing units, and administrative offices. The campus also includes a biotech lab, pilot plants, and quality control laboratories.

Biocon is known for its innovative products in areas such as diabetes, oncology, immunology, and cardiovascular diseases. Its main products include insulin, insulin analogs, immunosuppressants, monoclonal antibodies, and cancer therapies. The company also offers research services, contract manufacturing, and clinical development solutions to global pharmaceutical companies.

On a global scale, Biocon has established a strong presence with subsidiaries, joint ventures, and partnerships in various countries. It has subsidiaries like Biocon Biopharmaceuticals Pvt. Ltd in India, Biocon Malaysia Sdn.

Bhd in Malaysia, and Biocon SA in South Africa. The company has strategic partnerships with international pharmaceutical giants like Mylan, Bristol-Myers Squibb, and Sandoz, which have further enhanced its global footprint. Biocon holds a prominent market position in the biopharmaceutical industry.

It has consistently reported impressive sales growth and has become one of the top biopharmaceutical companies in Asia. Its global sales have been steadily increasing, with a significant portion coming from exports to developed markets like the United States and Europe. Over the years, Biocon has achieved several milestones and made significant changes to its product lineup.

In 2009, the company became the first Indian company to receive approval from the US Food and Drug Administration (FDA) for a generic version of a biologic drug. It has also received numerous regulatory approvals for its biosimilar products in various countries. Currently, Biocon is focusing on expanding its presence in emerging markets and strengthening its research and development capabilities.

It aims to become a global leader in biosimilars and continues to invest in cutting-edge technologies and collaborations with global partners to achieve this goal. In conclusion, Biocon is an Indian biopharmaceutical company that has steadily grown to become a major player in the global biopharmaceutical industry. With a diverse product portfolio, a strong global presence, and a focus on innovation, the company is well-positioned for future growth and success